Deep Dives

Why Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is a biotech force to be reckoned with

Regeneron

Regeneron was founded in 1988 by Dr. Leonard S Schleifer. Dr. Schelifer shared, that the name Regeneron came from “Regenerating neurons, with the word “gene” in the middle”. The origin of the name further explains that the initial focus of the company was neurobiology. Then in 1990 following the publication of its research in Science, the company announced a collaboration to develop neurotrophic factors.

However, the trials for the company’s neurotrophic factor didn’t go well. That’s when Regeneron refocused its efforts which have led to its success. Regeneron is now a vastly different company from when it started - Regeneron is more of a technology company than a drug company, staying true to its roots as a biotech.

The biotech has developed two high-value technologies platforms that it exploits to discover and develop its assets. The focus of these two platforms is on the discovery & development of antibody or antibody-like assets, which now make up all of Regeneron’s approved products and the bulk of its pipeline programs.

As such, these technology platforms are key assets for the company as it positions them favorably compared to its competitors. Let’s have a look at its two technology platforms.

Technology

West Pharmaceuticals (WST) - enabling pharmaceutical companies to get their products to their customers

Introduction West Pharmaceutical Services, Inc., founded in 1923 by Herman O. West, stands as a pioneering force in the global healthcare industry, with a rich history spanning nearly a century. Headquartered in Exton, Pennsylvania, West Pharma has evolved into a key player in providing innovative packaging components and delivery systems

Crucial Metrics to Monitor for Intuitive Surgical and a Valuation Analysis

A few months ago, we conducted an in-depth analysis of Intuitive Surgical (ISRG) and performed a preliminary valuation. In our most recent research, we dedicated time to a more comprehensive examination of Intuitive Surgical's growth prospects and financials. Our goal was to identify the essential factors that shape

Ascendis Pharma (ASND): Redefining Drug Delivery with TransCon

Introduction Ascendis Pharma is a biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs. The company was founded in 2007 and is headquartered in Copenhagen, Denmark, with offices in the United States. The

Technology

Read next